Replies to post #114141 on Amarin Corp Plc (AMRN)

[dmlcento]

Ralphey, do you prescribe drugs based on whether they have an interim analysis coming up? And if so, do you stop prescribing that drug if the decision is to continue the trial?

[HDGabor]

r-

I have posted this before ....

Continuation of the study only means one thing- results were not overwhelmingly positive to induce stoppage.

Yes, you posted this before and you were wrong before ... stopping rule wasn't about PE only ... wasn't about PE and robust and consistent SEs only ... it was:
- ss PE (as a gatekeeper for SEs analysis)
- robust and consistent SEs
AND
- rule out possible benefit of continuation.

Best,
G

[sts66]

since most new RX's are for trigs 200- 500 in hopes of reducing CAD

And you know this how, exactly? Many people here who sought a V scrip did not do it because of elevated TGs, myself included. If 1st A win allowing AMRN/Kowa reps to talk about ANCHOR results were driving NRx higher, we would have seen a noticeable change in the slope of NRx/TRx - but it didn't happen.

The real tragedy here is failure in study design. AMRN should have had included statin intolerant group.

This study design started back in the late 2000's, and including a non-statin group (for whatever reason) would have been a huge risk for AMRN, if they could even have found a couple thousand patients with established CVD or at high risk for developing it who weren't already taking statins - I seriously doubt they could have, because their doctors would have not been giving them the then current standard of care, risking malpractice.

Do you realize the majority of the medical establishment (still) refuses to believe that statin intolerance actually exists as a real medical condition? (it's not the statins making your muscles hurt, it's the exercise routine I put you on to reduce CVD risk)